reviewTop 1% cited
Strategies and challenges for the next generation of antibody–drug conjugates
Nature Reviews Drug Discovery · 2017 · Vol. 16(5) · pp. 315–337
Alain Beck✉(Center of Immunology Pierre Fabre)Liliane Goetsch(Center of Immunology Pierre Fabre)Charles Dumontet(Hospices Civils de Lyon)Nathalie Corvaı̈a(Center of Immunology Pierre Fabre)
HER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies ResearchChronic Lymphocytic Leukemia ResearchBrentuximab vedotinAntibody-drug conjugateDrugBioorthogonal chemistryConjugateDrug developmentPharmacologyMedicineChemistryAntibody
MeSH terms
TrastuzumabBrentuximab VedotinAdo-Trastuzumab EmtansineAnimalsAntibodies, MonoclonalAntigens, NeoplasmAntineoplastic AgentsDrug StabilityHumansMaytansineNeoplasmsDrug DesignImmunoconjugatesAntibodies, Monoclonal, Humanized
Citations
2,087
FWCI
98.79
field-weighted impact
References
178
Percentile
100%
vs. same field & year
Citations per year
Cited by
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Frontiers in Pharmacology · 2018 · 869 citations
Natural products in drug discovery: advances and opportunities
Nature Reviews Drug Discovery · 2021 · 4,708 citations
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Cancers · 2023 · 325 citations
Bioconjugation with Maleimides: A Useful Tool for Chemical Biology
Chemistry - A European Journal · 2018 · 484 citations
References
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
Oncotarget · 2015 · 458 citations
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
New England Journal of Medicine · 2015 · 9,308 citations
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
Breast Cancer Research and Treatment · 2010 · 528 citations
Microtubule-binding agents: a dynamic field of cancer therapeutics
Nature Reviews Drug Discovery · 2010 · 1,682 citations
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Clinical Cancer Research · 2004 · 1,196 citations
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Clinical Cancer Research · 2016 · 1,057 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.